These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 25170252)

  • 21. Particle size affects pharmacokinetics of milled oxycodone hydrochloride tablet products following nasal insufflation in nondependent, recreational opioid users.
    Raofi S; Kinjo M; Sun D; Li Z; Boyce H; Natarajan K; Frost M; Zhao L; Luke M; Lionberger R; Kelsh D; Kim MJ
    Clin Transl Sci; 2021 Sep; 14(5):1977-1987. PubMed ID: 33982418
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic Bioequivalence Studies of an Extended-Release Oxycodone Hydrochloride Tablet in Healthy Japanese Subjects Under Fasting and Fed Conditions Without an Opioid Antagonist.
    Toyama K; Furuie H; Kuroda K; Ishizuka H
    Drugs R D; 2017 Sep; 17(3):363-370. PubMed ID: 28516342
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized, double-blind, placebo-controlled study of the efficacy and safety of biphasic immediate-release/extended-release hydrocodone bitartrate/acetaminophen tablets for acute postoperative pain.
    Singla N; Margulis R; Kostenbader K; Zheng Y; Barrett T; Giuliani MJ; Chen Y; Young JL
    Phys Sportsmed; 2015 May; 43(2):126-37. PubMed ID: 25796986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single- and multiple-dose pharmacokinetics of biphasic immediate-release/extended-release hydrocodone bitartrate/acetaminophen (MNK-155) compared with immediate-release hydrocodone bitartrate/ibuprofen and immediate-release tramadol HCl/acetaminophen.
    Devarakonda K; Kostenbader K; Giuliani MJ; Young JL
    J Pain Res; 2015; 8():647-56. PubMed ID: 26508885
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential effects of food on the bioavailability of controlled-release oxycodone tablets and immediate-release oxycodone solution.
    Benziger DP; Kaiko RF; Miotto JB; Fitzmartin RD; Reder RF; Chasin M
    J Pharm Sci; 1996 Apr; 85(4):407-10. PubMed ID: 8901078
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of extended-release versus conventional tramadol/acetaminophen fixed-dose combination tablets: an open-label, 2-treatment, multiple-dose, randomized-sequence crossover study in healthy korean male volunteers.
    Yi S; Chung YJ; Kim TE; Shin HS; Yoon SH; Cho JY; Jang IJ; Shin SG; Yu KS
    Clin Ther; 2011 Jun; 33(6):728-37. PubMed ID: 21704237
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of pregabalin controlled-release in healthy volunteers: effect of food in five single-dose, randomized, clinical pharmacology studies.
    Chew ML; Plotka A; Alvey CW; Pitman VW; Alebic-Kolbah T; Scavone JM; Bockbrader HN
    Clin Drug Investig; 2014 Sep; 34(9):617-26. PubMed ID: 25078976
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the oral human abuse potential of Oxycodone DETERx® formulation (Xtampza® ER).
    Meske D; Kopecky EA; Passik S; Shram MJ
    J Opioid Manag; 2018; 14(5):359-372. PubMed ID: 30387859
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A nasal abuse potential randomized clinical trial of REMOXY® ER, a high-viscosity extended-release oxycodone formulation.
    Friedmann N; Marsman MR; de Kater AW; Burns LH; Webster LR
    J Opioid Manag; 2018; 14(6):437-443. PubMed ID: 30629280
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of physical manipulation on in vitro and in vivo release profiles of oxycodone DETERx®: an extended-release, abuse-deterrent formulation.
    Kopecky EA; Fleming AB; Noonan PK; Varanasi RK; Grima M; Saim S; Mayock SP
    J Opioid Manag; 2014; 10(4):233-46. PubMed ID: 25162603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A single-dose, 3-way crossover pharmacokinetic comparison between immediate-release oxycodone hydrochloride with aversion technology (IRO-A, Oxecta), IRO-a with Niacin, and Oxycodone Hydrochloride (Roxicodone) in healthy adults under fasting conditions.
    Leibowitz MT; Zamora CA; Brzeczko AW; Stark JG
    Am J Ther; 2014; 21(2):99-105. PubMed ID: 22357166
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of a New Amphetamine Extended-release Oral Liquid Suspension Under Fasted and Fed Conditions in Healthy Adults: A Randomized, Open-label, Single-dose, 3-treatment Study.
    Sikes C; Stark JG; McMahen R; Engelking D
    Clin Ther; 2017 Dec; 39(12):2389-2398. PubMed ID: 29174216
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of Subjective Effects with Systemic Opioid Exposure from Fixed-Dose Combinations of Oxycodone/Acetaminophen in Recreational Users of Prescription Drugs.
    Morton TL; Devarakonda K; Kostenbader K; Montgomery J; Barrett T; Webster L
    Pain Med; 2016 Mar; 17(3):539-550. PubMed ID: 26304767
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of single-dose and multiple-dose pharmacokinetics between two formulations of hydrocodone bitartrate/acetaminophen: immediate-release versus biphasic immediate-release/extended release.
    Devarakonda K; Kostenbader K; Giuliani MJ; Young JL
    J Pain Res; 2015; 8():607-18. PubMed ID: 26392786
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics and Safety of Levetiracetam Extended-Release Tablets and Relative Bioavailability Compared with Immediate-Release Tablets in Healthy Chinese Subjects.
    Wang M; Wang M; Zhang Q; Zong S; Lv C
    Eur J Drug Metab Pharmacokinet; 2018 Aug; 43(4):405-413. PubMed ID: 29383569
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Potential Role of an Extended-Release, Abuse-Deterrent Oxycodone/Acetaminophen Fixed-Dose Combination Product for the Treatment of Acute Pain.
    Pergolizzi JV; Taylor R; Raffa RB
    Adv Ther; 2015 Jun; 32(6):485-95. PubMed ID: 26026272
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extended-Release Once-Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate-Release Tofacitinib and Impact of Food.
    Lamba M; Wang R; Fletcher T; Alvey C; Kushner J; Stock TC
    J Clin Pharmacol; 2016 Nov; 56(11):1362-1371. PubMed ID: 26970526
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of ethanol on the pharmacokinetics of extended-release oxycodone with sequestered naltrexone (ALO-02).
    Malhotra BK; Matschke K; Wang Q; Bramson C; Salageanu J
    Clin Drug Investig; 2015 Apr; 35(4):267-74. PubMed ID: 25724154
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Positive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone in recreational opioid users.
    Schoedel KA; McMorn S; Chakraborty B; Potts SL; Zerbe K; Sellers EM
    J Opioid Manag; 2011; 7(3):179-92. PubMed ID: 21823549
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of an Extended-Release, Abuse-Deterrent, Microsphere-in-Capsule Analgesic for the Management of Patients with Chronic Pain With Dysphagia (CPD).
    Fleming AB; Carlson DR; Varanasi RK; Grima M; Mayock SP; Saim S; Kopecky EA
    Pain Pract; 2016 Mar; 16(3):334-44. PubMed ID: 25639548
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.